Pedro Carrilho-Ferreira

Publications (3)6.93 Total impact

• Article: Carcinoid Heart Disease: Outcome After Balloon Pulmonary Valvuloplasty.

  Pedro Carrilho-Ferreira, Doroteia Silva, Ana G Almeida, Eduardo Infante de Oliveira, Carlos Ferreira, Luís Miranda, Rosário Rosa, Pedro Canas da Silva, Henrique Bicha Castelo, António Nunes Diogo
  [show abstract] [hide abstract]
  ABSTRACT: Carcinoid heart disease typically presents with pulmonary stenosis and tricuspid regurgitation. Management is intended for symptomatic relief, and valvular intervention is indicated in refractory heart failure. Balloon valvuloplasty is an option for patients not suitable for surgery. We report the case of a patient with a carcinoid tumour, who developed postoperative refractory hypoxemia. Transthoracic echocardiogram revealed carcinoid pulmonary and tricuspid valve disease, with severe pulmonary stenosis. Balloon valvuloplasty was performed with major clinical improvement.
  The Canadian journal of cardiology 12/2012; · 3.36 Impact Factor
• Source

  Available from: Fausto J Pinto

  Article: Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction.

  Doroteia Silva, Nuno Cortez-Dias, Cláudia Jorge, J Silva Marques, Pedro Carrilho-Ferreira, Andreia Magalhães, Susana R Martins, Susana Gonçalves, Pedro Canas da Silva, Manuela Fiúza, António Nunes Diogo, Fausto J Pinto
  [show abstract] [hide abstract]
  ABSTRACT: Cystatin C is a marker of renal dysfunction, and preliminary studies have suggested it might have a role as a prognostic marker in patients with coronary artery disease. The aim of the present study was to evaluate the usefulness of cystatin C for risk stratification of patients with ST-segment elevation myocardial infarction, regarding in-hospital and long-term outcomes. We included 153 consecutive patients with ST-segment elevation myocardial infarction treated by primary angioplasty. The baseline cystatin C level was measured at coronary angiography. The in-hospital outcome was determined as progression to cardiogenic shock or in-hospital death, and the long-term outcome was assessed, considering the following end points: (1) death and (2) death or reinfarction. Of the 153 patients evaluated (age 61 ± 12 years; 75.6% men), 15 (14.4%) progressed to cardiogenic shock and 4 (2.7%) died during hospitalization. The patients who progressed to cardiogenic shock or died during hospitalization had significantly greater cystatin C levels (1.02 ± 0.44 vs 0.69 ± 0.24 mg/L; p = 0.001). Long-term follow-up was available for 130 patients (583 ± 163 days). Among them, 11 patients died and 7 had reinfarction. A high baseline cystatin C level was associated with an increased risk of death (hazard ratio 8.5; p = 0.009) and death or reinfarction (hazard ratio 3.89; p = 0.021). Furthermore, only high baseline cystatin C levels and left ventricular ejection fraction ≤40% were independent predictors of the long-term risk of death, with synergistic interaction between the 2. In conclusion, cystatin C is a new biomarker with significant added prognostic value for patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, predicting both short- and long-term outcomes.
  The American journal of cardiology 02/2012; 109(10):1431-8. · 3.58 Impact Factor
• Article: [Annulo-aortic ectasia imaging].

  Doroteia Silva, Pedro Carrilho-Ferreira, Susana Martins, Ana G Aimeida, Lena Neves, Pedro Canas da Silva, João Roque, Angelo Nobre, Maria José Correia, António Nunes Diogo
  Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology: an official journal of the Portuguese Society of Cardiology 02/2012; 31(3):253-4.